Cited below is the abstract for the new Aceves Group study, "Signalling Pathways Involved in the Antiproliferative effect of Molecular Iodine in Normal and Tumoral Breast Cells: Evidence that 6-Iodolactone Mediates Apoptotic Cells."
SUMMARY: Iodine exerts its cancer-killing capability in Breast Cancer cells by binding with high concentrations of polyunsaturated fats found in breast tumors.
1: Endocr Relat Cancer. 2008 Sep 30. [Epub ahead of print] Links
Signalling pathways involved in the antiproliferative effect of molecular Iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects.
Arroyo-Helguera O, Rojas E, Delgado G, Aceves C.
O Arroyo-Helguera, Instituto de Neurobiologia, UNAM-Juriquilla, Universidad Nacional Autonoma de Mexico, Juriquilla, Mexico.
Previous reports have documented the antiproliferative properties of molecular iodine (I2) and the arachidonic acid (AA) derivative 6-iodolactone (6-IL) in both thyroid and mammary gland. In this study, we characterized the cellular pathways activated by these molecules and their effects on cell cycle arrest and apoptosis in normal (MCF-12F) and cancerous (MCF-7) breast cells. Low to moderate concentrations of I2 (10-20 muM) cause G1 and G2/M phase arrest in MCF-12F, and caspase-dependent apoptosis in MCF-7 cells. In normal cells, only high doses of I2 (40 muM) induced apoptosis, and this effect was mediated by poly (ADP-ribose) polymerase-1 (PARP-1) and the apoptosis-induced factor (AIF), suggesting an oxidative influence of iodine at high concentrations. Our data indicate that both I2 and 6-IL trigger the same intracellular pathways and suggest that the antineoplasic effect of I2 in mammary cancer involves the intracellular formation of 6-IL. Mammary cancer cells are known to contain high concentrations of arachidonic acid, which might explain why I2 exerts apoptotic effects at lower concentrations only in tumoral cells.
PMID: 18827038 [PubMed - as supplied by publisher]